IDH wildtype glioblastoma often display increased human telomerase reverse transcriptase (hTERT) activity in both hTERT wildtype and mutation contexts that can be stimulated by NRF2, thereby preventing ROS-induced glioma cell death [248]. This evidence concerns the gene IDH1 and central nervous system cancer.